- Home
- EVC vs PBYI Comparison
EVC vs PBYI Comparison
Compare EVC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- PBYI
- Stock Information
- Founded
- EVC 1996
- PBYI 2010
- Country
- EVC United States
- PBYI United States
- Employees
- EVC N/A
- PBYI N/A
- Industry
- EVC Broadcasting
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- PBYI Health Care
- Exchange
- EVC Nasdaq
- PBYI Nasdaq
- Market Cap
- EVC 226.5M
- PBYI 171.7M
- IPO Year
- EVC 2000
- PBYI N/A
- Fundamental
- Price
- EVC $2.45
- PBYI $4.37
- Analyst Decision
- EVC
- PBYI Strong Buy
- Analyst Count
- EVC 0
- PBYI 1
- Target Price
- EVC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- EVC 224.7K
- PBYI 592.1K
- Earning Date
- EVC 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- EVC 8.06%
- PBYI N/A
- EPS Growth
- EVC N/A
- PBYI 434.29
- EPS
- EVC N/A
- PBYI 0.97
- Revenue
- EVC $396,704,000.00
- PBYI $238,062,000.00
- Revenue This Year
- EVC $64.06
- PBYI N/A
- Revenue Next Year
- EVC N/A
- PBYI N/A
- P/E Ratio
- EVC N/A
- PBYI $4.65
- Revenue Growth
- EVC 25.34
- PBYI 8.63
- 52 Week Low
- EVC $1.58
- PBYI $2.32
- 52 Week High
- EVC $2.73
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- EVC 49.30
- PBYI 43.78
- Support Level
- EVC $2.27
- PBYI $4.49
- Resistance Level
- EVC $2.62
- PBYI $4.72
- Average True Range (ATR)
- EVC 0.09
- PBYI 0.26
- MACD
- EVC -0.01
- PBYI -0.12
- Stochastic Oscillator
- EVC 51.43
- PBYI 4.00
About EVC Entravision Communications Corporation
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.